Tropical splenomegaly syndrome was later defined as hyperreactive malarial syndrome. Genetic factors, pregnancy, and malnutrition may play a role in the etiology of HMS. HMS is prevalent in native residents of regions where malaria is endemic.
Tropical splenomegaly syndrome was later defined as hyperreactive malarial syndrome. Genetic factors, pregnancy, and malnutrition may play a role in the etiology of HMS. HMS is prevalent in native residents of regions where malaria is endemic.
Tropical splenomegaly syndrome was later defined as hyperreactive malarial syndrome. Genetic factors, pregnancy, and malnutrition may play a role in the etiology of HMS. HMS is prevalent in native residents of regions where malaria is endemic.
Author: Vikramjit S Kanwar, MD, MBA, MRCP(UK), FAAP; Chief Editor: Robert J Arceci, MD, PhD
Background Several reports were published over the last century describing patients from tropical areas with massive splenomegaly. After excluding known causes of splenomegaly, tropical splenomegaly syndrome was defined as a separate entity. [1, 2, 3] This condition was later defined as hyperreactive malarial syndrome (HMS) using clear diagnostic criteria. [4, 5]
Young patient with hepatomegaly and massive splenomegaly. Pathophysiology HMS is prevalent in native residents of regions where malaria is endemic and visitors to those regions. Patients with HMS have high levels of antibody forPlasmodium falciparum, Plasmodium vivax, or Plasmodium ovale. [6]
Genetic factors, pregnancy, and malnutrition may play a role in the etiology of HMS. Relative protection against HMS is observed in patients with sickle cell trait, as it is with malaria. In experimental models, animals developed a similar syndrome after malarial infection. Although the exact mechanism is uncertain, evidence suggests that exposure to malaria elicits exaggerated stimulation of polyclonal B lymphocytes, leading to excessive and partially uncontrolled production of immunoglobulin M (IgM) as the initiating event. [7] IgM is polyclonal and is not specific for any particular malarial species. 2
Defective immunoregulatory control of B lymphocytes by suppressor or cytotoxic T lymphocytes causes the increase in B lymphocytes, although the mechanism by which malarial parasitemia drives these changes is unclear. [8] T-cell infiltration of the hepatic and splenic sinusoids accompanies this process. Serum cryoglobulin and autoantibody levels increase, as does the presence of high molecular weight immune complexes. The result is anemia, deposition of large immune complexes in Kupffer cells in the liver and spleen, reticuloendothelial cell hyperplasia, and hepatosplenomegaly. Antimalarial treatment is effective in decreasing the size of the spleen, but premature discontinuation of treatment may lead to relapse. Effective malarial chemoprophylaxis and eradication measures have been associated with a decrease in the incidence of HMS.
Epidemiology Frequency United States HMS occurs only in people who have resided in or who have visited areas where malaria is endemic. [9]
International HMS is restricted to native residents of and visitors to the malaria belt which roughly encompasses equatorial regions of South America, Africa, the Middle East, South Asia, and Southeast Asia. HMS has been reported in the following countries: Algiers Congo Madagascar Ivory Coast Sudan New Guinea Nigeria India Philippines Brazil China 3
Uganda Yemen Bangladesh Ethiopia Hong Kong Ghana Somalia Zambia Chile
Accurate assessment of the incidence of HMS is difficult because many conditions that cause splenomegaly are prevalent in areas where malaria is endemic. These conditions include hemoglobinopathies, lymphoreticular disorders,schistosomiasis, hepatic cirrhosis, leishmaniasis, typhoid, and tuberculosis. The incidence of massive splenomegaly is estimated to be 1-2% in rural Nigeria, [1] and HMS accounts for 11-45% of massive splenomegaly cases in Africa. [10, 11] The incidence of HMS is highest among the people of the Upper Watut Valley in Papua New Guinea, where the rate is estimated to be 80%. [12]
Mortality/Morbidity The natural history of HMS is not well documented. HMS is associated with a high mortality rate in untreated individuals; overwhelming infections are the leading cause of death. A 5-year mortality rate of 50% was reported in Uganda and New Guinea, [13] with a mortality of 85% in hospitalized patients. [6] However, other series found a much lower mortality rate. [14]
HMS is not a premalignant condition, although an overlap with chronic lymphocytic leukemia has been noted. [15] Whether HMS can undergo clonal evolution to splenic lymphoma with villous lymphocytes (SLVL) is unclear; these entities appear to evolve independently in response to chronic antigen stimulation. HMS has also been documented in patients with HIV infection and splenomegaly following the exclusion of other disease entities, such as Epstein-Barr virus,cytomegalovirus, or lymphoproliferative disorders. [16]
4
Race Certain racial and immunologic factors may be important in the pathogenesis of HMS, although results of phenotypic studies of human lymphocyte antigens have not been conclusive. The incidence of splenic enlargement at autopsy was greater in individuals who migrated from malaria-free Rwanda to malaria-endemic Uganda, than in local residents. Rwandan immigrants have also shown evidence of familial clustering, and many Rwandans with HMS were born and raised in the Baganda groups in Uganda. In Ghana, patients with HMS were more likely to have family members with splenomegaly. [17]
HMS has been reported in whites who resided in or moved to areas where malaria was endemic. It has also been described among visitors who received inadequate prophylaxis against malaria. [18]
Sex Overall, HMS is more common in female individuals, especially lactating mothers, than in male individuals, with a female-to-male ratio of 2:1. Only one study in Eastern Sudan showed men to have a higher incidence. [19]
Age HMS is most common in young and middle-aged adults, although the process probably commences during childhood. HMS is rare in children younger than 8 years but was reported in a 3-year-old patient. [20] These observations support the theory that chronic antigenic stimulation is an important factor in the development of HMS.
History The most common presenting symptoms of hyperreactive malarial syndrome (HMS), or tropical splenomegaly syndrome, are chronic abdominal swelling (64%) and pain (52%). [3] Abdominal swelling may wax and wane. Some patients present with acute abdominal pain. Pressure on the abdominal contents may also lead to hernias and leg swelling. A history of chronic splenic enlargement differentiates HMS from simple malarial splenomegaly. Almost all patients (97%) report weight loss. Patients physiologically adapt well to the chronic evolution of anemia and are symptomatic only when anemia is severe. Many patients do not have 5
any symptoms and are capable of normal daily activity. Weakness, loss of energy, and severe headache may signify severe anemia. Rarely, patients have intermittent fever. Persistent, severe fevers should raise the possibility of an alternative diagnosis. [20]
Bleeding complications such as epistaxis are uncommon because thrombocytopenia is usually not severe. Susceptibility to infections, especially skin and respiratory infections, is slightly increased. Pregnant women are susceptible to episodes of massive Coombs-negative hemolysis, which are usually preceded by febrile episodes. Coombs- positive hemolysis is associated rarely with acute attacks of plasmodium vivax malaria. [21]
Physical Patients are usually afebrile at presentation. Pallor is common, and the patient may be malnourished and jaundiced. In general, tachycardia is absent. If tachycardia is present, it indicates a concurrent complication. The hallmark of HMS is splenomegaly, which is usually moderate to massive. Most spleens (63%) are not tender, and almost all have a smooth surface, soft consistency, and sharp border. [19] The enlarged spleen may be seen to protrude against the abdominal wall, and a splenic bruit may be audible. Despite the size of the spleen, splenic rupture is rare. Hepatomegaly is common; in a study of 69 Nigerian patients, 93% had accompanying hepatomegaly. [3] Ascites is uncommon. Dilatation of the veins, cardiomegaly, low blood pressure, and flow murmurs reflect hypervolemia. Lymphadenopathy is absent, but bilateral parotid swelling has been described.
6
Causes The most important predisposing factor for HMS is residence in or visitation to an area where malaria is endemic. Other risk factors include malnutrition and an as-yet-undefined genetic predisposition.
Laboratory Studies Diagnostic criteria for hyperreactive malarial syndrome The mere exclusion of other disease processes causing splenomegaly is insufficient to establish a diagnosis of hyperreactive malarial syndrome (HMS). Fakunle was the first to establish diagnostic criteria for the definitive diagnosis of HMS. [3] Bates and Bedu-Addo refined these major criteria in 1997 to the current accepted list. [5] When these stricter criteria are applied, as many as one half of patients with splenomegaly may not have HMS. Major criteria include the following: Gross splenomegaly 10 cm or more below the costal margin in adults for which no other cause can be found Elevated serum IgM level 2 standard deviations or more above the local mean 7
Clinical and immunologic responses to antimalarial therapy Regression of splenomegaly by 40% by 6 months after start of therapy High antibody levels of Plasmodium species ( 1:800) Minor criteria include the following Hepatic sinusoidal lymphocytosis Normal cellular and humoral responses to antigenic challenge, including a normal phytohemagglutination response Hypersplenism Lymphocytic proliferation Familial occurrence
Hematologic manifestations Normocytic normochromic anemia is almost always present and is related to the degree of splenomegaly. Several factors contribute to its etiology, including pooling of RBCs in the spleen, hypersplenism, and increased RBC destruction and turnover; however, the major factor is increased plasma volume. The reticulocyte count is increased and reflects erythroid hyperplasia. The anemia is Coombs negative. Deficiency of vitamin B12, folic acid, or glucose-6-phosphate dehydrogenase has not been demonstrated. Leukopenia is common and is sometimes associated with lymphocytosis. Thrombocytopenia is generally mild. Both neutropenia and thrombocytopenia are due to splenic trapping. Peripheral smears usually do not reveal the malarial parasite.
Other findings IgM levels are increased. An elevation of 2 standard deviations above the local mean should be present. Serum IgM levels are correlated with the degree of splenomegaly. Patients with HMS have high titers of malarial antibodies. Titers of cold agglutinins, rheumatoid factor, antinuclear factor, cryoproteins, and thyroglobulins may be high. [22]
Serologies for cytomegalovirus (CMV), toxoplasmosis, Epstein-Barr virus (EBV), human herpesvirus 6 (HH6), parvovirus B19, and schistosomiasis may be false-positive. [23]
8
Imaging Studies Imaging tests are of limited value. Ultrasonography of the abdomen may help to document and monitor hepatosplenomegaly.
Other Tests Polymerase chain reaction (PCR) has been used to detect low-level parasitemia in patients with HMS, and multiplex PCR can identify the species of Plasmodiuminvolved. Because of its cost and complexity, this technique is not in widespread use. Unfortunately, simple rapid malaria tests, such as the ICT Malaria Test, often fail to detect the low level of antigenemia in HMS. [23]
A phytohemagglutination stimulation test may be helpful for differentiating HMS from lymphomas and chronic lymphocytic leukemia, for which the result is abnormal.
Histologic Findings Liver biopsy is rarely indicated. Hepatic sinusoidal lymphocytosis is present in HMS. Unlike with malaria, malarial pigmentation is absent in the macrophages in patients with HMS. This picture may also be present in infectious mononucleosis, hairy cell leukemia, malignant histiocytosis, and Felty syndrome. Kupffer cell hypertrophy and hyperplasia are also present.
Medical Care The mainstays of therapy are antimalarial drugs. Surgical Care Splenectomy plays no role in the treatment of hyperreactive malarial syndrome (HMS). The mortality rate after splenectomy is high because of fulminant and overwhelming infections. Consultations Appropriate consultation with oncologists and metabolic and infectious disease specialists may be sought to rule out diseases that mimic HMS. 9
Activity Activity is permitted, as tolerated by the patient. A patient's activity may be limited because of severe anemia or the pressure effects of massive splenomegaly.
Medication Summary Antimalarial drugs are effective in treating hyperreactive malarial syndrome (HMS). The specific drug of choice is based on the pattern and prevalence of drug resistance in the patient's geographic area. In endemic areas, treatment should be prolonged and continued regularly. Months may pass before a response is observed, and relapses may occur when therapy is discontinued. In expatriates returning with HMS, brief courses of treatment may be adequate. [18] To the authors' knowledge, no studies have addressed the duration of adequate treatment, and no researchers have compared antimalarial medications. Chloroquine and proguanil appear to be equally effective. This observation suggests that eradication of parasitemia is the common pathway for therapeutic responses. Pyrimethamine may be an alternative. [24] Data regarding the usefulness of other antimalarial drugs in HMS are limited. Short-term antimalarial treatment may be sufficient to treat patients who reside outside of an endemic region. The role of lifelong prophylaxis for individuals residing in endemic areas is unclear. Treatment may last more than one year or even longer. The response to therapy is guided by the size of spleen, a decrease in serum IgM levels, improvement of anemia, and general improvement in the patient's well-being. 10
Antimalarial Agents Class Summary Because epidemiologic and other data suggest that HMS is related to malarial infection, antimalarial drugs have been used and have been effective. View full drug information Chloroquine phosphate (Aralen Phosphate)
4-aminoquinolone widely used to treat malaria until recently, when resistant strains became major problems. Chloroquine and related drugs gametocidal (for species except for P falciparum) and schizonticidal (for parasites in blood but not tissue). Well absorbed PO. Best taken with food to decrease GI distress. View full drug information Proguanil (Paludrine)
Not available as single component in United States. Not prompt in relieving symptoms of acute malaria, but proguanil and related drugs (eg, pyrimethamine) effective against erythrocytic stages of malaria; they inhibit tetrahydrofolate dehydrogenase. Resistance to this group of drugs develops quickly. View full drug information Pyrimethamine and sulfadoxine (Fansidar) Combination product containing sulfadoxine 500 mg and 25 mg pyrimethamine. Mechanism of action for pyrimethamine same as that of proguanil (ie, inhibits dihydrofolate reductase). Pyrimethamine therapy, perhaps shortened, may rapidly decrease size of spleen. 11
Sulfonamides act in synergy with pyrimethamine; used together. Administer with folinic acid to decrease adverse effects.
Further Inpatient Care Because of the extended length of treatment often needed, monitoring for adverse effects is crucial. Splenectomy is contraindicated, because of increased infection-associated mortality. However, if the patient's spleen was previously removed, guidelines for the care of asplenic patients should be followed (see Asplenia). Guidelines include the following: Antibiotic prophylaxis Education Aggressive management of suspected episodes of fever Appropriate immunizations
Further Outpatient Care Regular visits are essential to monitor the patient's clinical improvement and to document decreases in splenomegaly. If chloroquine is used, monitor the patient for ophthalmologic effects with slit lamp, funduscopic, and visual field examinations. At regular intervals, perform cardiovascular monitoring with ECG and echocardiography, along with other tests as indicated. Further workup may be indicated to look for myopathy and peripheral neuritis. Liver function tests may be performed regularly if the patient is receiving proguanil. Resolution of splenomegaly is accompanied by an improvement of pancytopenia.
Inpatient & Outpatient Medications Antimalarials are the mainstays of treatment (see Medication). These drugs often need to be continued long-term (months to years). However, the exact length of treatment has not been ascertained. 12
Transfer Depending on the facilities available at the hospital, indications for transfer may be few. Medication can easily be started after the diagnosis is established. Supportive care, including blood transfusions and antibiotic therapy if indicated, is now commonplace in most hospitals.
Deterrence/Prevention For travelers to endemic areas, antimalarial prophylaxis is essential to minimize the risk of hyperreactive malarial syndrome (HMS). Prophylaxis for residents of endemic areas is controversial and has not been shown to prevent HMS. A study in Africa determined that the RTS,S/AS02D malaria vaccine was safe, well tolerated, and immunogenic in young infants. [25]
Complications Complications include infections that may be serious and that may result in death. Trapping of hematopoietic elements in the enlarged spleen may cause thrombocytopenia, anemia, and neutropenia, with resultant problems. A predisposition to develop malignancy remains unproven.
Prognosis HMS is a chronic disease that can be fatal because of infections and bleeding complications. Appropriate treatment with antimalarial medications can result in a good outcome. Splenectomy should be avoided because it increases the risk of fulminant infections. The risk of malignancy is ill defined.